The University of Kansas Cancer Center's podcast Bench to Bedside provides a glimpse into the latest research discoveries that are transforming cancer care. Join Roy Jensen, MD, vice chancellor and director of the cancer center, weekly to hear from the top experts in the field as well as patients and caregivers.
The History of KU Cancer Center with Dr. William Jewell
In this very special episode of the Bench to Bedside podcast, Dr. Roy Jensen hosts Dr. William Jewell, longtime surgeon and early leader of The University of Kansas Cancer Center, to recount how the center evolved from an uncertain idea into a nationally recognized program. Jewell describes early efforts after the 1971 Cancer Act, leadership transitions, and the challenges of aligning departments around a shared mission. Drawing on his NCI Subcommittee A experience and site visits, Jewell highlights that successful centers must show growth, collaboration, and an upward research trajectory.
00:00 Podcast Intro and Mission
00:18 Origin Story Setup
00:55 Meet Dr. William Jewell
02:11 Early War on Cancer Era
03:35 Leadership Changes
05:11 Building the Outpatient Center
06:25 NCI Pushback and Site Visit Experience
08:02 Internal Resistance and KU Lawrence Partnership
09:25 Recruiting Roy Jensen
12:04 Biggest Advances in Cancer Therapy
14:01 What Makes NCI Centers Succeed
16:17 Pride and the Role of Leadership
17:16 Masonic Support and Community Screenings
18:36 Closing Thanks and Looking Ahead
To ensure you get our latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center.
17 Jun 2026
Cancer Prevention Clinical Trials: Reducing Risk Before Diagnosis
In this episode of the Bench to Bedside podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, talks with Dr. Lauren Nye, medical oncologist and breast cancer prevention specialist, about cancer prevention clinical trials and how they differ from treatment trials by aiming to lower cancer risk or detect cancer earlier in healthy, high-risk individuals. Dr. Nye explains who may qualify based on family history, genetics, prior precancerous biopsies, or lifestyle factors, and highlights prevention successes, such as tamoxifen and the HPV vaccine. They discuss current research exploring well-tolerated, affordable options including GLP-1 receptor agonist, the heightened safety expectations for prevention studies, and why multi-agent approaches can be limited by toxicity. Dr. Nye also shares how she communicates risk—especially absolute versus relative risk—and encourages listeners to ask their doctor about risk assessment, genetic counseling, and high-risk clinics at KU Cancer Center.
00:00 Prevention Trials Intro
01:17 What Prevention Trials Are
02:08 Who Is High Risk
03:03 Why Prevention Matters
03:55 New Prevention Strategies
04:39 Drug Development Challenges
06:19 Patient Concerns and Safety
08:12 Why Not Combine Agents
10:10 Future of Prevention Research
11:53 Talking About Risk
13:24 Relative vs Absolute Risk
15:08 Next Steps and Wrap Up
Links from this Episode:
· Learn about cancer prevention and risk reduction options at KU Cancer Center
· See open cancer prevention clinical trials at KU Cancer Center
· Learn about Dr. Lauren Nye (https://www.kumc.edu/lnye.html)
· Read about breast cancer genetic counseling and testing at KU Cancer Center
To ensure you get our latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center.
3 Jun 2026
MyeloMATCH Update: Expanding Precision Medicine Access for AML Patients
In this episode of the Bench to Bedside podcast, Dr. Roy Jensen is joined by Dr. Tara Lin, principal investigator for the myeloMatch clinical trial at The University of Kansas Cancer Center, and Dr. Jesus Gonzalez Lugo, recently recognized with a National Career Development Award. They revisit the NCI-sponsored, first-of-its-kind national precision medicine trial for acute myeloid leukemia (AML) and share progress since its 2024 launch, including growth to five enrolling treatment protocols with seven more awaiting activation, more than 1,000 patients screened nationwide, and participation across 200+ U.S. sites. Dr. Lin explains how the master screening protocol returns comprehensive diagnostic results in 72 hours, improving treatment matching and access across KU Cancer Center's main campus, community satellites, and network sites. Dr. Lugo discusses outreach efforts to reduce barriers to trial participation, including education for physicians and patients, community partnerships, and Spanish-language media engagement, and both guests reflect on how myeloMatch could help guide use of the many new AML therapies now available.
00:00 Welcome Back to myeloMatch
01:09 Trial Growth and Milestones
02:58 How Precision Matching Works
04:57 Expanding Access Across Regions
06:15 Dr Lugo Award and Outreach
09:04 Future of AML Treatment
11:21 Closing and Resources
Links from this Episode:
· Listen to our first myeloMATCH episode, "MyeloMATCH: The New Front in the Battle Against Leukemia"
· Learn more about myeloMATCH
· Learn more about Dr. Tara Lin
· Learn more about Dr. Jesus Gonzalez Lugo
· Learn more about the Winn Career Development Award
To ensure you get our latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center.
Who has been a guest on Bench to Bedside
Names identified in recent episode analyses. Showing up to five guests.
David Akhavan
Paul Seyferth
Rebecca Keunen
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
YouTube views
383,460
Score snapshot 15 Sept 2025
Apple Podcasts (US)
4.2 / 5
5 ratings
Podcast Authority Score: 60 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
65
Social presence
0
YouTube
86
Engagement
51
Contact Bench to Bedside
Guest appearances
Does not typically book guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of Bench to Bedside?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
